Abstract
Misonidazole has been given to a total of 87 patients. Neurotoxicity has occurred--convulsions with the higher doses and peripheral neuropathy with the lowern ones. The data from 34 patients receiving 4--7 doses has been analysed. Peripheral neuropathy is related to the total tissue exposure. By monitoring serum levels and controlling the total dose given, convulsions are avoidable and peripheral neuropathy restricted to a low and acceptable level.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Foster J. L., Flockhart I. R., Dische S., Gray A., Lenox-Smith I., Smithen C. E. Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results. Br J Cancer. 1975 Jun;31(6):679–683. doi: 10.1038/bjc.1975.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gray A. J., Dische S., Adams G. E., Flockhart I. R., Foster J. L. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol. 1976 Apr;27(2):151–157. doi: 10.1016/s0009-9260(76)80137-7. [DOI] [PubMed] [Google Scholar]